Tamsulosin

Generic Name: Tamsulosin

Brand Names: Flomax, Jalyn

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₈N_₂O_₅S

CAS Number: 106133-20-4

Unique Ingredient Identifier: G3P28OML5I

Background: Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication: Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Clinical Trials

Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms

Phase 3

Not yet recruiting

Conditions: Stent Related Symptoms

Interventions: Drug: Terazosin
Drug: Tamsulosin

First Posted Date: 2025-05-13

Last Posted Date: 2025-05-18

Lead Sponsor: Penang Hospital, Malaysia

Target Recruit Count: 150

Registration Number: NCT06966804

Locations: 🇲🇾
Hospital Pulau Pinang, George Town, Pulau Pinang, Malaysia

L-Arginine Role for Stone Lower Ureter : A Randomized Control Study

Phase 4

Completed

Conditions: Stone Lower Ureter

Interventions: Drug: NSAID
Drug: L-Arginine, 500 Mg Oral Capsule
Drug: Tamsulosin 0.4 mg QD

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: Sohag University

Target Recruit Count: 153

Registration Number: NCT06753526

Locations: 🇪🇬
Faculty of medicine, Sohag University, Sohag, Egypt

The Safety and Effectiveness of Steep Pulse Therapy System for the Ablation of Benign Prostatic Hyperplasia

Not Applicable

Recruiting

Conditions: Benign Prostatic Hyperplasia

Interventions: Device: steep pulse therapy system
Drug: Tamsulosin Hydrochloride

First Posted Date: 2025-03-10

Last Posted Date: 2025-03-10

Lead Sponsor: First Affiliated Hospital of Zhejiang University

Target Recruit Count: 10

Registration Number: NCT06867315

Locations: 🇨🇳
The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China

Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy

Not Applicable

Recruiting

Conditions: Prostate Hyperplasia

Interventions: Drug: Tamsulosin Hydrochloride
Other: Sham

First Posted Date: 2025-03-07

Last Posted Date: 2025-03-24

Lead Sponsor: Ankara Training and Research Hospital

Target Recruit Count: 82

Registration Number: NCT06865430

Locations: 🇹🇷
Ankara bilkent city hospital, Ankara, Turkey

Peri-operative Tamsulosin and Impact on Voiding Trial After Same-day Urogynecology Surgery

Phase 3

Recruiting

Conditions: Postoperative Urinary Retention (POUR)

Interventions: Drug: Tamsulosin
Drug: Placebo

First Posted Date: 2025-02-25

Last Posted Date: 2025-02-25

Lead Sponsor: TriHealth Inc.

Target Recruit Count: 166

Registration Number: NCT06843538

Locations: 🇺🇸
TriHealth, Cincinnati, Ohio, United States

Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study

Phase 4

Completed

Conditions: BPH with Other Lower Urinary Tract Symptoms

Interventions: Drug: Tamsulosin 0.4 mg
Drug: Tadalafil 5mg
Drug: Tamsulosin and Tadalafil

First Posted Date: 2025-02-05

Last Posted Date: 2025-02-05

Lead Sponsor: Fayoum University Hospital

Target Recruit Count: 95

Registration Number: NCT06809205

Locations: 🇪🇬
Mohamed Mahmoud Dogha, Fayoum, Fayoum Governorate, Egypt

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

Phase 3

Not yet recruiting

Conditions: Ureteral Stent-Related Symptom

Interventions: Drug: Tamsulosin Hydrochloride 0.4 mg
Drug: Solifenacin Succinate 5 mg
Drug: Mirabegron 25 mg

First Posted Date: 2025-01-31

Last Posted Date: 2025-03-19

Lead Sponsor: Bir Hospital

Target Recruit Count: 189

Registration Number: NCT06803030

Locations: 🇳🇵
NAMS, Bir Hospital, Kathmandu, Bagmati, Nepal

Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study

Phase 3

Completed

Conditions: Lower Ureteric Stones

Interventions: Drug: Tamsulosin
Drug: Cetirizine
Combination Product: Cetirizine + Tamsulosin
Other: Placebo

First Posted Date: 2024-12-31

Last Posted Date: 2024-12-31

Lead Sponsor: South Valley University

Target Recruit Count: 480

Registration Number: NCT06754410

Locations: 🇪🇬
Qena university hospital, Qena, Egypt

Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.

Phase 3

Recruiting

Conditions: Posterior Urethral Valve

Interventions: Drug: Oxybutynin
Drug: Tamsulosin
Drug: Trimethoprim/sulfamethoxazole (TMP/SMZ)

First Posted Date: 2024-12-17

Last Posted Date: 2024-12-20

Lead Sponsor: Mansoura University

Target Recruit Count: 50

Registration Number: NCT06737016

Locations: 🇪🇬
Mansoura Urology and Nephrology Center, Mansoura, Dakahlia, Egypt

Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Not Applicable

Completed

Conditions: Lower Urinary Tract Symptoms
Prostatic Hyperplasia

Interventions: Drug: bovhyaluronidase azoximer
Drug: tamsulosin

First Posted Date: 2024-08-23

Last Posted Date: 2024-08-23

Lead Sponsor: NPO Petrovax

Target Recruit Count: 229

Registration Number: NCT06568718

Locations: 🇷🇺
LLC "Krasnodar Medical and Biological Center", Krasnodar, Russian Federation
🇷🇺
First Saint Petersburg State Medical University named after academician I.P. Pavlov, Saint Petersburg, Russian Federation
🇷🇺
LLC "Clinic of Modern Medicine of Dr. Bogorodskaya", Yaroslavl, Russian Federation

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy